PTAB denies Concert's challenge to Jakafi patent

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) said the U.S. Patent Trial and Appeal Board declined the company’s post grant review (PGR) petition challenging U.S. Patent No.

Read the full 244 word article

User Sign In